Symbol | Exchange | Currency |
|---|
By Samuel IndykInvesting.com – Avacta Group PLC (LON:AVCT) has announced the appointment of Dr Fiona McLaughlin as Chief Scientific Officer of its Therapeutics Division, effective...
Avacta is cautious about being able to repeat its stellar share price performance of 2020, but its results speak for themselves.Continue reading Avacta Group: can this share build...
By Samuel IndykInvesting.com – Avacta Group PLC (LON:AVTG) announced on Tuesday that they have entered into a global distribution agreement with Abcam PLC (LON:ABCA) to...
Here is a list of companies that were popular on the site in the latest week.British American TobaccoShares in British American Tobacco (LON:BATS) were popular on the site last...
GameStopThe GameStop Corp (NYSE:GME) squeeze was back this week amid hopes that the new stimulus checks will work their way into the stock market. After closing last week at...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Sell | Sell | Strong Sell | Sell |
| Technical Indicators | Strong Buy | Buy | Strong Sell | Buy | Strong Sell |
| Summary | Strong Buy | Neutral | Strong Sell | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 90.00 | 90.00 | 85.00 | +8.00 | +9.76% | 363.34K | London | |||
| 132.54 | 136.14 | 131.24 | -2.56 | -1.90% | 27.70M | London | |||
| 0.90 | 0.00 | 0.00 | +0.080 | +9.76% | 43.57K | London | |||
| 360.65 | 363.10 | 357.55 | +5.65 | +1.59% | 24.31M | London | |||
| 89.50 | 89.50 | 89.50 | -1.00 | -1.10% | 11.00K | London | |||
| 0.46 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00 | London | |||
| 53.45 | 57.10 | 52.00 | -4.00 | -7.02% | 1.12M | London | |||
| 0.01 | 0.00 | 0.00 | 0.0000 | 0.00% | 0.00 | London | |||
| 48.77 | 48.92 | 48.37 | +0.05 | +0.10% | 146.45M | London | |||
| 379.60 | 383.20 | 375.80 | +4.20 | +1.12% | 1.00M | London | |||
| 98.12 | 99.18 | 96.86 | +0.94 | +0.97% | 7.33M | London | |||
| 200.60 | 203.85 | 199.44 | +1.74 | +0.88% | 56.66M | London | |||
| 2,586.00 | 2,604.00 | 2,582.00 | +1.0 | +0.04% | 562.97K | London | |||
| 2,470.00 | 2,492.00 | 2,460.00 | +3.0 | +0.12% | 372.22K | London | |||
| 40.20 | 40.20 | 40.20 | +2.30 | +6.02% | 193.23K | London |
Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.